With a population of 1.3 billion people, China is both the world’s most populous nation and the fastest-growing major economy.
China has long had a reputation for low-cost labor and cheap exports. But according to a report from KPMG, China’s Pharmaceutical Industry Poised for the Giant Leap, China is turning away from this model and is focusing on socioeconomic development and resource sustainability.
The Chinese government laid out development goals in 2010 called the “125” plan, the country’s 12 Five-Year Plan (2011-2015), which places emphasis on greater welfare measures, public service, and more equitable distribution of wealth. Top priorities for the government are healthcare reform to ensure all citizens have basic medical coverage, modernizing the health infrastructure, improving…
China: The Top 20 Conditions
Regulatory Opportunities and Challenges
Francis Cao. Senior Director of Government Affairs and Public Relations, Beigene, a Chinese biotechnology company based in Beijing that is focused on discovering and developing innovative oncology drugs to address unmet medical needs in cancers that are prevalent in China and the Asia-Pacific region. For more information, visit beigene.com.
Marc Finn. Senior Director, Business Development, Suzhou Pharma Services, a contract development and manufacturing organization with its primary manufacturing site located in Suzhou, China. For more information, visit suzhoupharma.com.
Terry Hisey. Vice Chairman and U.S. Life Sciences Leader, Deloitte, which provides audit, consulting, financial advisory, risk management, and tax services. For more information, visit deloitte.com.
Clancey Houston. Managing Director, Chandler Chicco Companies’ China operations, which operates as inVentiv Health Communications company, is a multi-
disciplinary integrated communications group. For more information, visit chandlerchiccocompanies.com or inventivhealth.com.
Simon Li. General Manager, Kantar Health China, a global, evidence-based decision support partner to pharmaceutical, biotech, device, and diagnostic companies. For more information, visit kantarhealth.com.
Ling Zhen. General Manager, Quintiles, China, a fully integrated biopharma services company offering clinical, commercial, consulting, and capital solutions worldwide. For more information, visit quintiles.com.